Skip to main content
Premium Trial:

Request an Annual Quote

Sequenom in Danger of Being Demoted to Small-Cap Market

NEW YORK, Sept. 15 (GenomeWeb News) - Sequenom risks receiving a letter from the Nasdaq exchange warning the company of possible delisting if it fails to close above $1 by the end of the trading day on Sept. 17.

 

"There seems to be a threshold out there in the market place that is keeping us from closing above $1," said a Sequenom spokesperson. "We've hit above $1 a few times in the past week or so, but we haven't been able to close above $1."

 

The company also closed at $.99 on Sept. 14. The last time the company's stock closed above $1 was Aug. 5.

 

"Certainly we're making every effort to get the price above $1: increasing newsflow, meeting with the investment community to find some new buyers for stock, and fill some of the holes that have been created. That's the main plan, at the moment, to build demand for the stock," the spokesperson told GenomeWeb News.

 

If Sequenom fails to raise its share price above the $1 mark 90 days after receiving the letter, and maintain a closing price above the threshold for 10 trading days, it will be downgraded to the Nasdaq small-capitalization market. After that step, Sequenom would have to go through the same process, starting with closing above $1 in a 30-day period. Should it fail the second cycle, the company risks the delisting of its stock to the over-the-counter market.

The Scan

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.

Lupus Heterogeneity Highlighted With Single-Cell Transcriptomes

Using single-cell RNA sequencing, researchers in Nature Communications tracked down immune and non-immune cell differences between discoid lupus erythematosus and systemic lupus erythematosus.

Rare Disease Clues Gleaned From Mobile Element Insertions in Exome Sequences

With an approach called MELT, researchers in the European Journal of Human Genetics uncovered mobile element insertions in exomes from 3,232 individuals with or without developmental or neurological abnormalities.

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.